Nogo‑B receptor in relevant carcinoma: Current achievements, challenges and aims (Review)

Li,Yu-Kun; Xie,Yuan‑Jie; Wu,Dai-Chao; Long,Shuang-Lian; Tang,Shengsong; Mo,Zhong-Cheng

doi:10.3892/ijo.2018.4520

Nogo‑B receptor in relevant carcinoma: Current achievements, challenges and aims (Review)

Authors:
- Yu-Kun Li
- Yuan‑Jie Xie
- Dai-Chao Wu
- Shuang-Lian Long
- Shengsong Tang
- Zhong-Cheng Mo
View Affiliations

Affiliations: Department of Histology and Embryology, Clinical Anatomy and Reproductive Medicine Application Institute, University of South China, Hengyang, Hunan 421001, P.R. China, Department of Pharmacology, Hunan University of Medicine, Huaihua, Hunan 418000, P.R. China
Published online on: August 9, 2018 https://doi.org/10.3892/ijo.2018.4520
Pages: 1827-1835

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The novel neurite outgrowth inhibitor B (Nogo‑B) receptor (NgBR) is specific for Nogo‑B, which is highly expressed in various human organs and cells, including the lung, liver, kidney, smooth muscle cells, blood vessel endothelial cells and inflammatory cells. Previous studies have indicated that NgBR directly interacts with Nogo‑B and is able to independently influence lipid and cholesterol homeostasis, angiogenesis, N‑glycosylation, the epithelial-mesenchymal transition, the chemotaxis of endothelial cells and cellular proliferation and apoptosis. These multiple functions and actions of this receptor provide an understanding of the important roles of NgBR in various conditions, including fatty liver, atherosclerosis, intracranial microaneurysms, retinitis pigmentosa and severe neurological impairment. Furthermore, NgBR has been demonstrated to exert protean, multifunctional and enigmatic effects in cancer. The present review summarizes the latest knowledge on the suppressing and activating effects of NgBR, emphasizing its function in cancer. Further basic and medical research on this receptor may provide novel insight into its clinical implications on the prognosis of relevant human cancer types.

View Figures

View References

1	Miao RQ, Gao Y, Harrison KD, Prendergast J, Acevedo LM, Yu J, Hu F, Strittmatter SM and Sessa WC: Identification of a receptor necessary for Nogo-B stimulated chemotaxis and morphogenesis of endothelial cells. Proc Natl Acad Sci USA. 103:10997–11002. 2006. View Article : Google Scholar : PubMed/NCBI
2	Rana U, Liu Z, Kumar SN, Zhao B, Hu W, Bordas M, Cossette S, Szabo S, Foeckler J, Weiler H, et al: Nogo-B receptor deficiency causes cerebral vasculature defects during embryonic development in mice. Dev Biol. 410:190–201. 2016. View Article : Google Scholar : PubMed/NCBI
3	Long SL, Li YK, Xie YJ, Long ZF, Shi JF and Mo ZC: Neurite outgrowth inhibitor B receptor: A versatile receptor with multiple functions and actions. DNA Cell Biol. 36:1142–1150. 2017. View Article : Google Scholar : PubMed/NCBI
4	Dodd DA, Niederoest B, Bloechlinger S, Dupuis L, Loeffler JP and Schwab ME: Nogo-A, -B, and -C are found on the cell surface and interact together in many different cell types. J Biol Chem. 280:12494–12502. 2005. View Article : Google Scholar : PubMed/NCBI
5	Li M and Song J: Nogo-B receptor possesses an intrinsically unstructured ectodomain and a partially folded cytoplasmic domain. Biochem Biophys Res Commun. 360:128–134. 2007. View Article : Google Scholar : PubMed/NCBI
6	Schwab ME: Nogo and axon regeneration. Curr Opin Neurobiol. 14:118–124. 2004. View Article : Google Scholar : PubMed/NCBI
7	Holcomb J, Doughan M, Spellmon N, Lewis B, Perry E, Zhang Y, Nico L, Wan J, Chakravarthy S, Shang W, et al: SAXS analysis of a soluble cytosolic NgBR construct including extracellular and transmembrane domains. PLoS One. 13:e01913712018. View Article : Google Scholar : PubMed/NCBI
8	Szafranski P, Von Allmen GK, Graham BH, Wilfong AA, Kang SH, Ferreira JA, Upton SJ, Moeschler JB, Bi W, Rosenfeld JA, et al: 6q22.1 microdeletion and susceptibility to pediatric epilepsy. Eur J Hum Genet. 23:173–179. 2015. View Article : Google Scholar :
9	Grabińska KA, Park EJ and Sessa WC: cis-prenyltransferase: new insights into protein glycosylation, rubber synthesis, and human diseases. J Biol Chem. 291:18582–18590. 2016. View Article : Google Scholar
10	Park EJ, Grabińska KA, Guan Z and Sessa WC: NgBR is essential for endothelial cell glycosylation and vascular development. EMBO Rep. 17:167–177. 2016. View Article : Google Scholar : PubMed/NCBI
11	Hu W, Zhang W, Chen Y, Rana U, Teng RJ, Duan Y, Liu Z, Zhao B, Foeckler J, Weiler H, et al: Nogo-B receptor deficiency increases liver X receptor alpha nuclear translocation and hepatic lipogenesis through an adenosine monophosphate-activated protein kinase alpha-dependent pathway. Hepatology. 64:1559–1576. 2016. View Article : Google Scholar : PubMed/NCBI
12	Park EJ, Grabińska KA, Guan Z, Stránecký V, Hartmannová H, Hodaňová K, Barešová V, Sovová J, Jozsef L, Ondrušková N, et al: Mutation of Nogo-B receptor, a subunit of cis-prenyltransferase, causes a congenital disorder of glycosylation. Cell Metab. 20:448–457. 2014. View Article : Google Scholar : PubMed/NCBI
13	Eckharter C, Junker N, Winter L, Fischer I, Fogli B, Kistner S, Pfaller K, Zheng B, Wiche G, Klimaschewski L, et al: Schwann cell expressed Nogo-B modulates axonal branching of adult sensory neurons through the Nogo-B receptor NgBR. Front Cell Neurosci. 9:4542015. View Article : Google Scholar : PubMed/NCBI
14	Wang B, Zhao B, North P, Kong A, Huang J and Miao QR: Expression of NgBR is highly associated with estrogen receptor alpha and survivin in breast cancer. PLoS One. 8:e780832013. View Article : Google Scholar : PubMed/NCBI
15	Dong C, Zhao B, Long F, Liu Y, Liu Z, Li S, Yang X, Sun D, Wang H, Liu Q, et al: Nogo-B receptor promotes the chemoresistance of human hepatocellular carcinoma via the ubiquitination of p53 protein. Oncotarget. 7:8850–8865. 2016. View Article : Google Scholar : PubMed/NCBI
16	Calik J, Pula B, Piotrowska A, Wojnar A, Witkiewicz W, Grzegrzolka J, Podhorska-Okolow M and Dziegiel P: Prognostic significance of NOGO-A/B and NOGO-B receptor expression in malignant melanoma - A preliminary study. Anticancer Res. 36:3401–3407. 2016.PubMed/NCBI
17	Pula B, Werynska B, Olbromski M, Muszczynska-Bernhard B, Chabowski M, Janczak D, Zabel M, Podhorska-Okolow M and Dziegiel P: Expression of Nogo isoforms and Nogo-B receptor (NgBR) in non-small cell lung carcinomas. Anticancer Res. 34:4059–4068. 2014.PubMed/NCBI
18	Zhao B, Xu B, Hu W, Song C, Wang F, Liu Z, Ye M, Zou H and Miao QR: Comprehensive proteome quantification reveals NgBR as a new regulator for epithelial-mesenchymal transition of breast tumor cells. J Proteomics. 112:38–52. 2015. View Article : Google Scholar :
19	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
20	Pula B, Olbromski M, Owczarek T, Ambicka A, Witkiewicz W, Ugorski M, Rys J, Zabel M, Dziegiel P and Podhorska-Okolow M: Nogo-B receptor expression correlates negatively with malignancy grade and ki-67 antigen expression in invasive ductal breast carcinoma. Anticancer Res. 34:4819–4828. 2014.PubMed/NCBI
21	Maluccio M and Covey A: Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin. 62:394–399. 2012. View Article : Google Scholar : PubMed/NCBI
22	Kuo TC, Chang PY, Huang SF, Chou CK and Chao CC: Knockdown of HURP inhibits the proliferation of hepacellular carcinoma cells via downregulation of gankyrin and accumulation of p53. Biochem Pharmacol. 83:758–768. 2012. View Article : Google Scholar : PubMed/NCBI
23	Elder DE: Melanoma screening and mortality. J Natl Cancer Inst. Mar 29–2018.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
24	Lee JH, Miele ME, Hicks DJ, Phillips KK, Trent JM, Weissman BE and Welch DR: KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst. 88:1731–1737. 1996. View Article : Google Scholar : PubMed/NCBI
25	Wu D, Zhao B, Qi X, Peng F, Fu H, Chi X, Miao QR and Shao S: Nogo-B receptor promotes epithelial-mesenchymal transition in non-small cell lung cancer cells through the Ras/ERK/Snail1 pathway. Cancer Lett. 418:135–146. 2018. View Article : Google Scholar : PubMed/NCBI
26	Cui J, He W, Yi B, Zhao H, Lu K, Ruan H and Ma D: mTOR pathway is involved in ADP-evoked astrocyte activation and ATP release in the spinal dorsal horn in a rat neuropathic pain model. Neuroscience. 275:395–403. 2014. View Article : Google Scholar : PubMed/NCBI
27	Zhao B, Chun C, Liu Z, Horswill MA, Pramanik K, Wilkinson GA, Ramchandran R and Miao RQ: Nogo-B receptor is essential for angiogenesis in zebrafish via Akt pathway. Blood. 116:5423–5433. 2010. View Article : Google Scholar : PubMed/NCBI
28	Zhao B, Hu W, Kumar S, Gonyo P, Rana U, Liu Z, Wang B, Duong WQ, Yang Z, Williams CL, et al: The Nogo-B receptor promotes Ras plasma membrane localization and activation. Oncogene. 36:3406–3416. 2017. View Article : Google Scholar : PubMed/NCBI
29	Inoue K and Fry EA: Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer. Int J Cancer. 139:33–41. 2016. View Article : Google Scholar : PubMed/NCBI
30	Ryu HW, Shin DH, Lee DH, Won HR and Kwon SH: A potent hydroxamic acid-based, small-molecule inhibitor A452 preferentially inhibits HDAC6 activity and induces cytotoxicity toward cancer cells irrespective of p53 status. Carcinogenesis. 39:72–83. 2018. View Article : Google Scholar
31	Abraham AG and O’Neill E: PI3K/Akt-mediated regulation of p53 in cancer. Biochem Soc Trans. 42:798–803. 2014. View Article : Google Scholar : PubMed/NCBI
32	Jo M, Lester RD, Montel V, Eastman B, Takimoto S and Gonias SL: Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling. J Biol Chem. 284:22825–22833. 2009. View Article : Google Scholar : PubMed/NCBI
33	Brabletz T: EMT and MET in metastasis: Where are the cancer stem cells? Cancer Cell. 22:699–701. 2012. View Article : Google Scholar : PubMed/NCBI
34	Larue L and Bellacosa A: Epithelial-mesenchymal transition in development and cancer: Role of phosphatidylinositol 3′ kinase/ AKT pathways. Oncogene. 24:7443–7454. 2005. View Article : Google Scholar : PubMed/NCBI
35	Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL and Arteaga CL: Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem. 275:36803–36810. 2000. View Article : Google Scholar : PubMed/NCBI
36	Wendt MK, Smith JA and Schiemann WP: Transforming growth factor-β-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. Oncogene. 29:6485–6498. 2010. View Article : Google Scholar : PubMed/NCBI
37	Yang L, Han S and Sun Y: An IL6-STAT3 loop mediates resistance to PI3K inhibitors by inducing epithelial-mesenchymal transition and cancer stem cell expansion in human breast cancer cells. Biochem Biophys Res Commun. 453:582–587. 2014. View Article : Google Scholar : PubMed/NCBI
38	Song Q, Jiang S, Zhang X, Pan C, Lu C, Peng J and Li Q: Radiosensitivity of human ovarian cancer cells is enhanced by pseudolaric acid B due to the inhibition of the Ras/Raf/ERK signaling pathway. Exp Ther Med. 15:685–690. 2018.PubMed/NCBI
39	Sriskanthadevan-Pirahas S, Lee J and Grewal SS: The EGF/ Ras pathway controls growth in Drosophila via ribosomal RNA synthesis. Dev Biol. 439:19–29. 2018. View Article : Google Scholar : PubMed/NCBI
40	Takahashi-Niki K, Kato-Ose I, Murata H, Maita H, Iguchi-Ariga SM and Ariga H: Epidermal growth factor-dependent activation of the extracellular signal-regulated kinase pathway by DJ-1 protein through its direct binding to c-Raf protein. J Biol Chem. 290:17838–17847. 2015. View Article : Google Scholar : PubMed/NCBI
41	Rotblat B, Belanis L, Liang H, Haklai R, Elad-Zefadia G, Hancock JF, Kloog Y and Plowman SJ: H-Ras nanocluster stability regulates the magnitude of MAPK signal output. PLoS One. 5:e119912010. View Article : Google Scholar : PubMed/NCBI
42	Roy S, Luetterforst R, Harding A, Apolloni A, Etheridge M, Stang E, Rolls B, Hancock JF and Parton RG: Dominant-negative caveolin inhibits H-Ras function by disrupting cholesterol-rich plasma membrane domains. Nat Cell Biol. 1:98–105. 1999. View Article : Google Scholar : PubMed/NCBI
43	Jin Y, Hu W, Liu T, Rana U, Aguilera-Barrantes I, Kong A, Kumar SN, Wang B, Gao P, Wang X, et al: Nogo-B receptor increases the resistance of estrogen receptor positive breast cancer to paclitaxel. Cancer Lett. 419:233–244. 2018. View Article : Google Scholar : PubMed/NCBI
44	Buday L and Downward J: Many faces of Ras activation. Biochim Biophys Acta. 1786:178–187. 2008.PubMed/NCBI
45	Prior IA and Hancock JF: Ras trafficking, localization and compartmentalized signalling. Semin Cell Dev Biol. 23:145–153. 2012. View Article : Google Scholar :
46	Karadedou CT, Gomes AR, Chen J, Petkovic M, Ho KK, Zwolinska AK, Feltes A, Wong SY, Chan KY, Cheung YN, et al: FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer. Oncogene. 31:1845–1858. 2012. View Article : Google Scholar
47	Sherbet GV: Suppression of angiogenesis and tumour progression by combretastatin and derivatives. Cancer Lett. 403:289–295. 2017. View Article : Google Scholar : PubMed/NCBI
48	Mantovani G, Macciò A, Madeddu C, Gramignano G, Lusso MR, Serpe R, Massa E, Astara G and Deiana L: A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/ cachexia and oxidative stress. Cancer Epidemiol Biomarkers Prev. 15:1030–1034. 2006. View Article : Google Scholar : PubMed/NCBI
49	Saharinen P, Eklund L, Pulkki K, Bono P and Alitalo K: VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med. 17:347–362. 2011. View Article : Google Scholar : PubMed/NCBI
50	Vasudevan D and Thomas DD: Insights into the diverse effects of nitric oxide on tumor biology. Vitam Horm. 96:265–298. 2014. View Article : Google Scholar : PubMed/NCBI
51	Ricciuti B, Foglietta J, Bianconi V, Sahebkar A and Pirro M: Enzymes involved in tumor-driven angiogenesis: A valuable target for anticancer therapy. Semin Cancer Biol. Nov 8–2017, (Epub ahead of print). S1044-579X(17)30043-3. pp. 2017 View Article : Google Scholar
52	Teng RJ, Rana U, Afolayan AJ, Zhao B, Miao QR and Konduri GG: Nogo-B receptor modulates angiogenesis response of pulmonary artery endothelial cells through eNOS coupling. Am J Respir Cell Mol Biol. 51:169–177. 2014.PubMed/NCBI
53	Jo HN, Kang H, Lee A, Choi J, Chang W, Lee MS and Kim J: Endothelial miR-26a regulates VEGF-Nogo-B receptor-mediated angiogenesis. BMB Rep. 50:384–389. 2017. View Article : Google Scholar : PubMed/NCBI
54	Cruz P, Torres C, Ramírez ME, Epuñán MJ, Valladares LE and Sierralta WD: Proliferation of human mammary cancer cells exposed to 27-hydroxycholesterol. Exp Ther Med. 1:531–536. 2010. View Article : Google Scholar : PubMed/NCBI
55	Furberg AS, Veierød MB, Wilsgaard T, Bernstein L and Thune I: Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J Natl Cancer Inst. 96:1152–1160. 2004. View Article : Google Scholar
56	Alikhani N, Ferguson RD, Novosyadlyy R, Gallagher EJ, Scheinman EJ, Yakar S and LeRoith D: Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model. Oncogene. 32:961–967. 2013. View Article : Google Scholar
57	Ooi K, Shiraki K, Sakurai Y, Morishita Y and Nobori T: Clinical significance of abnormal lipoprotein patterns in liver diseases. Int J Mol Med. 15:655–660. 2005.PubMed/NCBI
58	Rice SJ, Liu X, Miller B, Joshi M, Zhu J, Caruso C, Gilbert C, Toth J, Reed M, Rassaei N, et al: Proteomic profiling of human plasma identifies apolipoprotein E as being associated with smoking and a marker for squamous metaplasia of the lung. Proteomics. 15:3267–3277. 2015. View Article : Google Scholar : PubMed/NCBI
59	Repa JJ and Mangelsdorf DJ: The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol. 16:459–481. 2000. View Article : Google Scholar : PubMed/NCBI
60	Shackelford DB: Unravelling the connection between metabolism and tumorigenesis through studies of the liver kinase B1 tumour suppressor. J Carcinog. 12:162013. View Article : Google Scholar : PubMed/NCBI
61	Hardie DG, Schaffer BE and Brunet A: AMPK: An Energy-Sensing Pathway with Multiple Inputs and Outputs. Trends Cell Biol. 26:190–201. 2016. View Article : Google Scholar
62	Hardie DG: AMPK: A target for drugs and natural products with effects on both diabetes and cancer. Diabetes. 62:2164–2172. 2013. View Article : Google Scholar : PubMed/NCBI
63	He G, Zhang YW, Lee JH, Zeng SX, Wang YV, Luo Z, Dong XC, Viollet B, Wahl GM and Lu H: AMP-activated protein kinase induces p53 by phosphorylating MDMX and inhibiting its activity. Mol Cell Biol. 34:148–157. 2014. View Article : Google Scholar :
64	Li W, Saud SM, Young MR, Chen G and Hua B: Targeting AMPK for cancer prevention and treatment. Oncotarget. 6:7365–7378. 2015.PubMed/NCBI
65	Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ and Thompson CB: AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell. 18:283–293. 2005. View Article : Google Scholar : PubMed/NCBI
66	Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
67	Handa N, Takagi T, Saijo S, Kishishita S, Takaya D, Toyama M, Terada T, Shirouzu M, Suzuki A, Lee S, et al: Structural basis for compound C inhibition of the human AMP-activated protein kinase α2 subunit kinase domain. Acta Crystallogr D Biol Crystallogr. 67:480–487. 2011. View Article : Google Scholar : PubMed/NCBI
68	Hadad SM, Baker L, Quinlan PR, Robertson KE, Bray SE, Thomson G, Kellock D, Jordan LB, Purdie CA, Hardie DG, et al: Histological evaluation of AMPK signalling in primary breast cancer. BMC Cancer. 9:3072009. View Article : Google Scholar : PubMed/NCBI
69	Zhang W, Yang X, Chen Y, Hu W, Liu L, Zhang X, Liu M, Sun L, Liu Y, Yu M, et al: Activation of hepatic Nogo-B receptor expression-A new anti-liver steatosis mechanism of statins. Biochim Biophys Acta. 1863.177–190. 2018.
70	Grabińska KA, Edani BH, Park EJ, Kraehling JR and Sessa WC: A conserved carboxy-terminal RxG motif in the NgBR subunit of cis-prenyltransferase is critical for prenyltransferase activity. J Biol Chem. 292:17351–17361. 2017. View Article : Google Scholar
71	Boersema PJ, Geiger T, Wisniewski JR and Mann M: Quantification of the N-glycosylated secretome by super-SILAC during breast cancer progression and in human blood samples. Mol Cell Proteomics. 12:158–171. 2013. View Article : Google Scholar :
72	Li N, Xu H, Fan K, Liu X, Qi J, Zhao C, Yin P, Wang L, Li Z and Zha X: Altered β1,6-GlcNAc branched N-glycans impair TGF-β-mediated epithelial-to-mesenchymal transition through Smad signalling pathway in human lung cancer. J Cell Mol Med. 18:1975–1991. 2014. View Article : Google Scholar : PubMed/NCBI
73	Chen CY, Jan YH, Juan YH, Yang CJ, Huang MS, Yu CJ, Yang PC, Hsiao M, Hsu TL and Wong CH: Fucosyltransferase 8 as a functional regulator of nonsmall cell lung cancer. Proc Natl Acad Sci USA. 110:630–635. 2013. View Article : Google Scholar
74	Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Yoshimastu T, Morita M and Yasumoto K: Expression of endoplasmic reticulum molecular chaperone Grp78 in human lung cancer and its clinical significance. Lung Cancer. 49:55–62. 2005. View Article : Google Scholar : PubMed/NCBI
75	Kim KM, Yu TK, Chu HH, Park HS, Jang KY, Moon WS, Kang MJ, Lee DG, Kim MH, Lee JH, et al: Expression of ER stress and autophagy-related molecules in human non-small cell lung cancer and premalignant lesions. Int J Cancer. 131:E362–E370. 2012. View Article : Google Scholar
76	Lin Y, Wang Z, Liu L and Chen L: Akt is the downstream target of GRP78 in mediating cisplatin resistance in ER stress-tolerant human lung cancer cells. Lung Cancer. 71:291–297. 2011. View Article : Google Scholar
77	Clarke R, Cook KL, Hu R, Facey CO, Tavassoly I, Schwartz JL, Baumann WT, Tyson JJ, Xuan J, Wang Y, et al: Endoplasmic reticulum stress, the unfolded protein response, autophagy, and the integrated regulation of breast cancer cell fate. Cancer Res. 72:1321–1331. 2012.PubMed/NCBI
78	Meng XX, Yao M, Zhang XD, Xu HX and Dong Q: ER stress-induced autophagy in melanoma. Clin Exp Pharmacol Physiol. 42:811–816. 2015. View Article : Google Scholar : PubMed/NCBI
79	Martin S, Hill DS, Paton JC, Paton AW, Birch-Machin MA, Lovat PE and Redfern CP: Targeting GRP78 to enhance melanoma cell death. Pigment Cell Melanoma Res. 23:675–682. 2010. View Article : Google Scholar : PubMed/NCBI
80	Matsumoto T, Uchiumi T, Monji K, Yagi M, Setoyama D, Amamoto R, Matsushima Y, Shiota M, Eto M and Kang D: Doxycycline induces apoptosis via ER stress selectively to cells with a cancer stem cell-like properties: Importance of stem cell plasticity. Oncogenesis. 6:3972017. View Article : Google Scholar : PubMed/NCBI